3D-Lab: a collaborative web-based platform for molecular modeling

被引:23
作者
Grebner, Christoph [1 ]
Norrby, Magnus [1 ]
Enstrom, Jonatan [1 ]
Nilsson, Ingemar [1 ]
Hogner, Anders [1 ]
Henriksson, Jonas [2 ]
Westin, Johan [2 ]
Faramarzi, Farzad [2 ]
Werner, Philip [2 ]
Bostrom, Jonas [1 ]
机构
[1] AstraZeneca, CVMD iMED, Med Chem Dept, S-43183 Molndal, Sweden
[2] AstraZeneca, Res Discovery Informat, S-43183 Molndal, Sweden
关键词
3D visualization; drug design; high-performance computing; molecular modeling; open source; usability; virtual reality; virtual screening; DOCKING; SITES;
D O I
10.4155/fmc-2016-0081
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Aim: The use of 3D information has shown impact in numerous applications in drug design. However, it is often under-utilized and traditionally limited to specialists. We want to change that, and present an approach making 3D information and molecular modeling accessible and easy-to-use 'for the people'. Methodology/results: A user-friendly and collaborative web-based platform (3D-Lab) for 3D modeling, including a blazingly fast virtual screening capability, was developed. 3D-Lab provides an interface to automatic molecular modeling, like conformer generation, ligand alignments, molecular dockings and simple quantum chemistry protocols. 3D-Lab is designed to be modular, and to facilitate sharing of 3D-information to promote interactions between drug designers. Recent enhancements to our open-source virtual reality tool Molecular Rift are described. Conclusion: The integrated drug-design platform allows drug designers to instantaneously access 3D information and readily apply advanced and automated 3D molecular modeling tasks, with the aim to improve decision-making in drug design projects.
引用
收藏
页数:14
相关论文
共 20 条
[1]   The Cambridge Structural Database: a quarter of a million crystal structures and rising [J].
Allen, FH .
ACTA CRYSTALLOGRAPHICA SECTION B-STRUCTURAL SCIENCE, 2002, 58 (3 PART 1) :380-388
[2]  
Anastas P., 1998, GREEN CHEM THEORY PR
[3]   The process of structure-based drug design [J].
Anderson, AC .
CHEMISTRY & BIOLOGY, 2003, 10 (09) :787-797
[4]  
[Anonymous], MOL DRUG PROPERTIES
[5]   The Protein Data Bank [J].
Berman, HM ;
Westbrook, J ;
Feng, Z ;
Gilliland, G ;
Bhat, TN ;
Weissig, H ;
Shindyalov, IN ;
Bourne, PE .
NUCLEIC ACIDS RESEARCH, 2000, 28 (01) :235-242
[6]   Assessing the performance of OMEGA with respect to retrieving bioactive conformations [J].
Boström, J ;
Greenwood, JR ;
Gottfries, J .
JOURNAL OF MOLECULAR GRAPHICS & MODELLING, 2003, 21 (05) :449-462
[7]   Analysis of Past and Present Synthetic Methodologies on Medicinal Chemistry: Where Have All the New Reactions Gone? [J].
Brow, Dean G. ;
Bostrom, Jonas .
JOURNAL OF MEDICINAL CHEMISTRY, 2016, 59 (10) :4443-4458
[8]   Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy [J].
Friesner, RA ;
Banks, JL ;
Murphy, RB ;
Halgren, TA ;
Klicic, JJ ;
Mainz, DT ;
Repasky, MP ;
Knoll, EH ;
Shelley, M ;
Perry, JK ;
Shaw, DE ;
Francis, P ;
Shenkin, PS .
JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (07) :1739-1749
[9]  
Frisch M. J. E. A., 2009, Gaussian 09, revision d. 01, DOI DOI 10.12691/WJOC-5-1-2
[10]   AstexViewer™:: a visualisation aid for structure-based drug design [J].
Hartshorn, MJ .
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 2002, 16 (12) :871-881